The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 20, 2025
Daily News
October 20, 2025
- No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
October 20, 2025
- Payers, Providers Clash over Fate of Fee Premiums for Generic Use
October 20, 2025
- Meiji Completes New Facilities to Restart Domestic Production of 6-APA
October 20, 2025
- Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
October 20, 2025
- iPark, KoreaBIO Ink MOU to Fuel Japan-Korea Cooperation in Life Sciences
October 20, 2025
- Novo, JAST Join Hands to Raise Awareness of Obesity
October 20, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…